- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02083068
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study is a prospective controlled, blinded clinical trial, designed to establish the protective efficacy induced by the vaccine PvCSP between human volunteers with and without history of malaria.
Study subjects
This study will require the involvement of two types of volunteers:
- Parasite donors: 5-15 P. vivax-infected patients who will serve as parasites donors for experimental infection of mosquitoes, who will be enrolled in the endemic area.
- Volunteers for immunization: Two other groups of volunteers will be immunized with the vaccine PvCSP. A group of 16 people without previous exposure to malaria (naive) and another 16 people with a history of previous malaria infection (pre-immune).
Methodology Recruitment of infected patients: Parasite donors will be recruited among P. vivax infected patients attending a diagnostic center in the endemic area.
Infection of mosquitoes Blood from donors will be used to feed three days old mosquitoes by artificial membrane feeding technique. At day 7 a sample of mosquitoes will be examined to determine the degree of infection by dissection of the mosquito gut. On day 14, a small amount of mosquitoes with a good degree of infectivity will be used to infect challenged volunteers.
Recruitment of pre-immune and naive volunteers: Volunteers for the immunization stage will be recruited both in the city of Cali, non-endemic region, and in Buenaventura, a malaria endemic region, through various activities such as conferences, meetings and other means approved by the IRB like posters and flyers.
Immunization: Volunteers will be immunized with the vaccine (n=16) or placebo (n=16).
Follow Up Volunteers will be under medical vigilance during the first hour following the immunization to detect any adverse reaction. After the first hour period a medical exam will be made. Eight hours after immunization, each volunteer will be telephoned to assess physical condition. Any adverse event (AE) will be registered.
Subsequent follow up will be made on the day next to immunization and 1 or 2 weeks before the next immunization by a new clinical evaluation and AE report. Volunteers will be educated to contact the research staff at any moment.
Infection of volunteers Immunized volunteers will be challenged on day ~150 of the study, 1 month after the third immunization by the bite of 3±1 infected mosquitos. The "feeding cage" will be placed on the forearm of a volunteer for 10 minutes, allowing that the feeding window, wich will be covered by a mesh surface be placed against the volunteer's skin.
Volunteers will be educated about the signs and symptoms of malaria and they will have a daily telephone contact during the first 6 days.
Between days 7 and 23 the volunteers will be asked to go to the Clinical Trials Unit daily in order to establish the presence or absence of disease through thick blood smear and samples will be collected for retrospective real time PCR P. vivax.
From day 23 until day 31, volunteers will receive physical and laboratory evaluation every other day and will have daily telephone contact.
Once the patients present signs and symptoms of the disease curative treatment will be immediately provided, and 15 ml of blood will be drawn, which will be used for immune response assessment.
If the volunteers do not develop the disease during the follow-up period, on day 31 they will be given antimalarial treatment.
Treatment Volunteers will be treated with antimalarial drugs approved by the Colombian Ministry of Social Protection: chloroquine (three (3) doses: 600 mg initially, followed by 450mg at 24, and 48 hours), associated with primaquine (30mg/día) for 14 days. All the volunteers will be asked to return two weeks after starting treatment for a thick blood smear test to ensure cure of malaria.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, Colombia
- Malaria Vaccine and Drug Development Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Naïve group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign.
Not have a history of malaria infection. For women, use of adequate contraception from the star restriction to be lifted by a doctor for contraception study. Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco ,Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Being Duffy positive ( Fy +) . Levels of hemoglobin ( Hb) > 11 g / dl. Availability to participate during the period in which they develop the study. Do not be participating in another clinical study
2. Preimmune group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign .
Having a history of infection (s ) and serological tests for malaria positive for P. vivax.
For women, use adequate contraception from the start restriction to be lifted by a doctor for contraception study .
Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Availability to participate during the period in which they develop the study.
3. Voluntary blood donors
- Healthy men and women aged 18-45 years.
- Be positive diagnosis of P. vivax determined by thick smear examination .
- The patient must not have circulating malaria parasites such as P. falciparum or P. malariae .
- Have a parasitemia ≥ 0.1 %. by thick smear .
- Hb ≥ 9 g / dL at the time of diagnosis of malaria.
- The patient must have the capacity to provide informed consent freely and voluntarily . Should be illiterate may assert its decision to participate by putting their fingerprint in the format consent. Minors who are between 15 and 17 and wishing to participate must sign the informed consent and one of its Parents must sign the informed consent, accompanied by 2 witnesses who also sign
Exclusion Criteria:
Step 1
- Negative IFAT (< 1:20) for P. vivax on screening tests
- Other criteria used in the case of naive volunteers, except a history of having lived in an endemic area for the past 6 months.
Step 2 Patients that have chronic or acute disease, different from malaria by P. vivax.
Having a history of disease or clinical conditions that according to medical criteria might increase significantly the risk related with participation on this study Hemoglobin levels <9 g/dL at the time of recruitment Have received antimalarial treatment before the diagnosis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Experimental
10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
|
Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015
At month 2 and 6
Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015,
at month 0
|
Placebo komparator: Control
six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
|
SSN Montanide ISA-51 1 mL
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
Tidsramme: Thirty days after the last immunization
|
Vaccine protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
|
Thirty days after the last immunization
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Evolution of antibody titers
Tidsramme: At months 0, 2, 4 and 6 of the trial
|
Follow up every 2 months (month 0, 2, 4 and 6) until the end of the trial will be done to assess the evolution of P. vivax antibody titers.
|
At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction
Tidsramme: At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction will be measured by IFN- γ, TNF-α, IL-2; IL- 4, IL-6, IL-10
|
At months 0, 2, 4 and 6 of the trial
|
Changes on vaccine biological security
Tidsramme: On the day next to immunization and 1 or 2 weeks before the next immunization
|
Changes on vaccine biological security will be measured by renal, hepatic and hematologic function and pregnancy test.
|
On the day next to immunization and 1 or 2 weeks before the next immunization
|
Antibody functionality in vitro through inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
Tidsramme: Every 2 months
|
Antibody functionality will be tested in vitro through essays of inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
|
Every 2 months
|
Vaccine-induced protection for P. vivax
Tidsramme: 28 days after mosquito bites
|
Vaccine-induced protection for P. vivax will be assessed by pre-patent period onset after infected mosquito bites exposure
|
28 days after mosquito bites
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Generelle publikationer
- Herrera S, Solarte Y, Jordan-Villegas A, Echavarria JF, Rocha L, Palacios R, Ramirez O, Velez JD, Epstein JE, Richie TL, Arevalo-Herrera M. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4-11. doi: 10.4269/ajtmh.2011.09-0498.
- Arevalo-Herrera M, Gaitan X, Larmat-Delgado M, Caicedo MA, Herrera SM, Henao-Giraldo J, Castellanos A, Devaud JC, Pannatier A, Onate J, Corradin G, Herrera S. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nat Commun. 2022 Mar 25;13(1):1603. doi: 10.1038/s41467-022-29226-3.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2304-493-26202
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts... og andre samarbejdspartnereRekrutteringPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLaos Demokratiske Folkerepublik
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis... og andre samarbejdspartnereAfsluttetMalaria | Vivax malaria | Falciparum malariaEtiopien, Bangladesh, Indonesien
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanAfsluttetVivax malaria | Ukompliceret Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaAfsluttetPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology og andre samarbejdspartnereAfsluttet
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AfsluttetVivax malaria | Falciparum malariaIndonesien
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet TPO og andre samarbejdspartnereAfsluttetMalaria | Vivax malaria | Falciparum malariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AfsluttetVivax malaria | Falciparum malariaIndonesien
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationAfsluttetMalaria | Vivax malaria | Falciparum malaria | Malaria Genopblomstring
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute for Advanced Medical Research and Training, University of Ibadan, IbadanAfsluttetPlasmodium Falciparum Malaria | Ukompliceret malaria | Malaria feberNigeria
Kliniske forsøg med Vaccine PvCS N+C+R
-
Malaria Vaccine and Drug Development CenterAsoclinic Inmunología Ltda.; Centro médico ImbanacoAfsluttet
-
TidalSenseNational Institute for Health Research, United Kingdom; Innovate UKAfsluttetSund og rask | Bronkiektasi | Anæmi | Astma | Lungekræft | Interstitiel lungesygdom | KOL | Lang COVID | Øvre luftvejssygdom | Kongestiv hjertesvigtDet Forenede Kongerige
-
Universidad Nacional Autonoma de MexicoRekrutteringTelerehabilitering | Neuropsykologi | HIV DemensMexico
-
WockhardtAfsluttetType I diabetesForenede Stater, Indien
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes... og andre samarbejdspartnereRekrutteringKardiomyopati | Amyloidose, primærForenede Stater
-
Medical University of ViennaRekrutteringHyperemesis Gravidarum | Kvalme Gravidarum | C-vitamin mangelØstrig
-
University of North Carolina, Chapel HillWakeMed Health and HospitalsAfsluttetGraviditet | Ikke-insulinafhængig diabetesForenede Stater
-
Omaima Mossad Mahmoud AL-SherbiniAfsluttetSmerter, postoperativ | Gingival recession | Patienttilfredshed | Donorside | Åbent sår i ganen uden komplikationer | Gratis tandkødstransplantater | Mucogingival defekterEgypten
-
NYU Langone HealthNational Eye Institute (NEI)AfsluttetGrøn stær | Øjensygdomme | Aldersrelateret makuladegeneration | Diabetisk retinopati | Central serøs chorioretinopati | Grøn stær, mistænktForenede Stater
-
Changhua Christian HospitalMinistry of Science and Technology, Taiwan; Intuitive SurgicalUkendtBrystkræft kvindeTaiwan, Korea, Republikken, Italien